SEO URLwww.firestrike.ai/deals/arcellx-gilead-sciences-acquisition-2026-31
acquisitionAnnounced · Feb 24, 2026biotechnologySource · CredibleArticle · Factual
Gilead Sciences acquires Arcellx
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
$7.8B
Target
Arcellx
NASDAQ: ACLX · Redwood City, California
Acquirer
Gilead Sciences
Full Acquisition
Status
Announced
Gilead Sciences agreed to acquire Arcellx. Reported deal value: $7.8B. Status: Announced. Sector: biotechnology. Target headquarters context: Redwood City, California, United States.
This page summarizes publicly available information about the transaction as of 2026-02-24. Figures and status may change as filings and press coverage update.
Credit: Sundry Photography / Shutterstock.com Gilead Sciences is expanding its CAR-T therapy partnership with Arcellx by acquiring the US biotech for $7.8 billion
Deal timeline
Announced
Feb 24, 2026 · europeanpharmaceuticalreview.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in biotechnology with a reported deal value of $7.8B. Figures and status may change as sources update.
Sources: europeanpharmaceuticalreview.com · Primary article · FireStrike proprietary index